Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 1/20 | 0.40 |
| ▸ | TK1 | P04183 | 1/20 | 0.40 |
| ▸ | PDE9A | O76083 | 11/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | POLA1 | P09884 | 1/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13889499 | 1.00 | TK2 (0.40) | TK2TK1PDE9ACDK4CCND1 | |
| SCHEMBL889767 | 0.83 | CDK4 (0.42) | PDE9ACDK4CCND1PDE1CPDE1B | |
| SCHEMBL26298197 | 0.82 | ALDH1A1 (0.44) | TK2TK1POLA1 | |
| SCHEMBL13166486 | 0.81 | TK1 (0.41) | TK2TK1POLA1 | |
| SCHEMBL12601707 | 0.80 | PDE9A (0.34) | PDE9ACDK4CCND1PDE1CPDE1B | |
| SCHEMBL13889498 | 0.80 | PDE9A (0.34) | PDE9ACDK4CCND1PDE1CPDE1B | |
| SCHEMBL23786492 | 0.79 | ADRB1 (0.47) | TK2TK1POLA1 | |
| SCHEMBL12123502 | 0.79 | ADRB1 (0.47) | TK2TK1POLA1 | |
| SCHEMBL889695 | 0.79 | ADRB1 (0.47) | TK2TK1POLA1 | |
| SCHEMBL14570606 | 0.79 | ADRB1 (0.47) | TK2TK1POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943752-B2 | Modified oligonucleotides and applications thereof | Applied Biosystems, L.L.C. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090226924-A1 | Modified Oligonucleotides and Applications Thereof | APPLERA CORPORATION | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226924-A1 | Modified Oligonucleotides and Applications Thereof | RNGTT, POLRMT, POLM | TK2 107/4885TK1 170/4885PDE9A 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.